Safety and Immunogenicity of Cervarix in Human Immunodeficiency Virus Infected Females

Trial Profile

Safety and Immunogenicity of Cervarix in Human Immunodeficiency Virus Infected Females

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 19 May 2017

At a glance

  • Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary) ; Human papillomavirus vaccine recombinant quadrivalent Merck
  • Indications Cervical cancer; Human papillomavirus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 May 2017 This trial has been completed in Estonia (end date: 19 Apr 2017).
    • 02 Jun 2015 Planned number of patients changed from 600 to 708 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top